Abstract:e14276 Background: Adjuvant chemotherapy has been established as a standard for patients with early stage NSCLC after complete tumor resection, but the 5-year survival rate can only increase by about 5%. Given its high morbidity and mortality, new biomarkers are needed to predict clinical response and prognosis of resected NSCLC. The expression of MHC-I, PD-L1 and CD8+ TILs were detected in this study to investigate the potential prognostic markers in patients with early stage NSCLC. Methods: Tissue of 125 patients with surgically resected NSCLC (stage I-III) were obtained from the First Hospital of Jilin Universtiy. MHC-I, PD-L1 and CD8+ TILs were detected with immunohistochemistry. The association between their expression levels and patients’ prognosis was analyzed. Results: MHC-I was down-expressed, and PD-L1 was up-expressed in NSCLC tissues compared with the para-cancer tissues. CD8+ TILs could be seen in tumor stroma and nest. PFS and OS was poorer in MHC-Ilow group compared with MHC-Ihigh group (P < 0.05). PFS and OS in PD-L1− group tended to be longer than the PD-L1+ group, but the difference was not significant (P > 0.05). For CD8+ TILs, PFS and OS of the CD8inflamed group were longer than the CD8non-inflamed group (P < 0.05). With multivariate analysis, we found that MHC-I and CD8+ TILs might be independent prognostic factors of NSCLC (P < 0.05). Based on the PD-L1 and CD8+ TILs expression, we divided the patients into four subgroups: PD-L1+/CD8inflamed, PD-L1+/CD8non-inflamed, PD-L1−/CD8inflamed, and PD-L1−/CD8non-inflamed. Statistical differences were achieved both in PFS and OS (P < 0.05). PFS and OS of the PD-L1+/CD8inflamed and PD-L1−/CD8inflamed group were longer than the other two groups. Patients with PD-L1+/CD8non-inflamed experienced the worst PFS and OS. Besides, we divided the patients into four subgroups according to their MHC-I and CD8+ TILs expression conditions: MHC-Ihigh/CD8inflamed, MHC-Ihigh/CD8non-inflamed, MHC-Ilow /CD8inflamed, and MHC-Ilow/CD8non-inflamed. Statistical differences were achieved both in PFS and OS of these subgroups (P < 0.05). PFS and OS of the MHC-Ihigh/CD8inflamed group were longer than the other three groups. Patients in MHC-Ilow/CD8non-inflamed group experienced the worst PFS and OS. Conclusions: It was reported for the first time that the combination of PD-L1 and CD8+ TILs, MHC-I and CD8+ TILs suggested impressive prognostic values in early stage NSCLC in this study. The comprehensive analysis of immune indicators may provide prognostic markers for early stage NSCLC.

Combined tumor‐associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma

Author Response for "combined Tumor‐associated Macrophages Biomarker Predicting Extremely Poor Outcome of Patients with Primary Central Nervous System Lymphoma"

Decreased peripheral blood lymphocyte-monocyte ratio and platelet-monocyte ratio and the Peripheral Blood Score model predict poor survival in peripheral T-cell lymphoma patients

The prognostic value of CD8+ CTLs, CD163+ TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma

Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis

Predictive and Prognostic Significance of M Descriptors of the 8th TNM Classification for Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors.

Prognostic Value of Clinical Characteristics and Immunophenotypic Biomarkers in 115 Patients with Primary Central Nervous System Lymphoma.

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

[Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].

Spatial interaction and functional status of CD68+SHP2+ macrophages in tumor microenvironment correlate with overall survival of NSCLC

Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC

Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma

Interstitial Tumor-Associated Macrophages Combined with Tumor-Derived Colony-Stimulating Factor-1 and Interleukin-6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer.

Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma

Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients

Comprehensive Analysis of Immune Indicators Provides Prognostic Markers for Early Stage Non-Small Cell Lung Cancer.

New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL)

Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma